Physician profile
Mark Riner
NPI 1275521221
$2,889.95
in general payments reported to CMS, 2019-2025
26 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $103 · 2021: $35.97 · 2022: $447 · 2023: $645 · 2024: $566 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.27 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.11 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $319.98 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $164.10 | 2019-2025 | Tremfya, Simponi, Stelara |
| Phathom Pharmaceuticals, INC. | $123.06 | 2024-2025 | Voquezna |
| Celgene Corporation | $120.89 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $91.70 | 2019-2025 | Ocaliva |
| Vivus LLC | $74.70 | 2019-2023 | Qsymia |
| Olympus America INC. | $69.10 | 2022-2025 | Endoclot Phs, Hanarostent Esophagus Tts(Ccc), Single Use Ligating Device |
| Gilead Sciences, INC. | $61.16 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $52.81 | 2019-2023 | Linzess |
| Aimmune Therapeutics, INC. | $51.13 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $41.18 | 2024-2025 | Resmetirom, Rezdiffra |
| Novo Nordisk INC | $39.80 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $37.08 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.25 | 2019 | |
| Exact Sciences Corporation | $32.94 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $29.59 | 2023 | Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $29.18 | 2024 | Rebyota |
| Genzyme Corporation | $25.33 | 2024 | |
| Braintree Laboratories, INC. | $22.63 | 2023 | Sutab |
| Celltrion USA INC. | $20.23 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $19.86 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $18.18 | 2024 | Dupixent |
| Pentax of America, INC. | $17.58 | 2023 | C2 Cryoballoon |
| Ethicon US, LLC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Riner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.